定义非酒精性脂肪性肝病中肝脂肪变、炎症、气球样变和纤维化的血清蛋白质组特征
研究采用改良适配体蛋白质组学技术检测636例经组织学确诊的非酒精性脂肪性肝病(NAFLD)患者的2852份血清样本中的5220种蛋白质,建立并验证了针对脂肪变、气球样变、小叶炎症和纤维化的二分法蛋白质-表型模型。四种模型在训练集/配对验证集中的AUC分别为纤维化0.92/0.85、脂肪变0.95/0.79、炎症0.83/0.72、气球样变0.87/0.83;高危NASH的AUC为0.93/0.85。组件模型评分在活性药物治疗后较安慰剂显著改善,并可区分维生素E、吡格列酮和奥贝胆酸的不同效应。
要点
- 基于37种分析物(其中18种此前未与NAFLD关联)的蛋白质模型可诊断NAFLD关键组织学特征。
- 纤维化模型AUC在训练集/验证集为0.92/0.85,脂肪变为0.95/0.79,炎症为0.83/0.72,气球样变为0.87/0.83。
- 高危NASH模型AUC为0.93/0.85,组件模型评分在活性药物治疗后较安慰剂显著改善。
核心结论
- 血清蛋白质扫描识别出与NAFLD肝活检关键组分对应的特征,所建模型对三种不同药物干预的纵向变化具有足够敏感性。
- 这些数据支持继续验证这些蛋白质组模型,以实现基于「液体活检」的NAFLD评估。
研究设计与样本
- 采用改良适配体蛋白质组学技术,检测636例经组织学确诊的NAFLD患者的2852份单次血清样本中的5220种蛋白质。
- 开发并验证二分法蛋白质-表型模型,用于识别脂肪变(0级 vs 1-3级)、肝细胞气球样变(0 vs 1或2)、小叶炎症(0-1 vs 2-3)和纤维化(0-1期 vs 2-4期)的临床相关严重程度。
主要发现
- 四种蛋白质模型基于37种分析物(18种此前未与NAFLD关联),在训练集/配对验证集中诊断各自组分的AUC为:纤维化0.92/0.85,脂肪变0.95/0.79,炎症0.83/0.72,气球样变0.87/0.83。
- 高危NASH定义为脂肪性肝炎伴NAFLD活动度评分≥4(各组分评分至少1分)且纤维化分期≥2,通过将各组分模型输出相乘进行预测,AUC为0.93/0.85。
- 组件模型评分在活性药物治疗后较安慰剂显著改善,并识别出维生素E、吡格列酮和奥贝胆酸的不同效应。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Despite recent progress, non-invasive tests for the diagnostic assessment and monitoring of non-alcoholic fatty liver disease (NAFLD) remain an unmet need. Herein, we aimed to identify diagnostic signatures of the key histological features of NAFLD. METHODS: Using modified-aptamer proteomics, we assayed 5,220 proteins in each of 2,852 single serum samples from 636 individuals with histologically confirmed NAFLD. We developed and validated dichotomized protein-phenotype models to identify clinically relevant severities of steatosis (grade 0 vs. 1-3), hepatocellular ballooning (0 vs. 1 or 2), lobular inflammation (0-1 vs. 2-3) and fibrosis (stages 0-1 vs. 2-4). RESULTS: The AUCs of the four protein models, based on 37 analytes (18 not previously linked to NAFLD), for the diagnosis of their respective components (at a clinically relevant severity) in training/paired validation sets were: fibrosis (AUC 0.92/0.85); steatosis (AUC 0.95/0.79), inflammation (AUC 0.83/0.72), and ballooning (AUC 0.87/0.83). An additional outcome, at-risk NASH, defined as steatohepatitis with NAFLD activity score ≥4 (with a score of at least 1 for each of its components) and fibrosis stage ≥2, was predicted by multiplying the outputs of each individual component model (AUC 0.93/0.85). We further evaluated their ability to detect change in histology following treatment with placebo, pioglitazone, vitamin E or obeticholic acid. Component model scores significantly improved in the active therapies vs. placebo, and differential effects of vitamin E, pioglitazone, and obeticholic acid were identified. CONCLUSIONS: Serum protein scanning identified signatures corresponding to the key components of liver biopsy in NAFLD. The models developed were sufficiently sensitive to characterize the longitudinal change for three different drug interventions. These data support continued validation of these proteomic models to enable a "liquid biopsy"-based assessment of NAFLD. CLINICAL TRIAL NUMBER: Not applicable. IMPACT AND IMPLICATIONS: An aptamer-based protein scan of serum proteins was performed to identify diagnostic signatures of the key histological features of non-alcoholic fatty liver disease (NAFLD), for which no approved non-invasive diagnostic tools are currently available. We also identified specific protein signatures related to the presence and severity of NAFLD and its histological components that were also sensitive to change over time. These are fundamental initial steps in establishing a serum proteome-based diagnostic signature of NASH and provide the rationale for using these signatures to test treatment response and to identify several novel targets for evaluation in the pathogenesis of NAFLD.
引用
- Sanyal AJ, Williams SA, Lavine JE, et al. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2022. PMID: 36528237. doi:10.1016/j.jhep.2022.11.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。